CN113233976A - Gallic acid and aminoacetic acid eutectic and whitening cream containing eutectic - Google Patents

Gallic acid and aminoacetic acid eutectic and whitening cream containing eutectic Download PDF

Info

Publication number
CN113233976A
CN113233976A CN202110499029.9A CN202110499029A CN113233976A CN 113233976 A CN113233976 A CN 113233976A CN 202110499029 A CN202110499029 A CN 202110499029A CN 113233976 A CN113233976 A CN 113233976A
Authority
CN
China
Prior art keywords
gallic acid
acid
aminoacetic
eutectic
aminoacetic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110499029.9A
Other languages
Chinese (zh)
Other versions
CN113233976B (en
Inventor
涂禄清
邓建科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Cuipu Biotechnology Co ltd
Original Assignee
Guangzhou Cuipu Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Cuipu Biotechnology Co ltd filed Critical Guangzhou Cuipu Biotechnology Co ltd
Priority to CN202110499029.9A priority Critical patent/CN113233976B/en
Publication of CN113233976A publication Critical patent/CN113233976A/en
Application granted granted Critical
Publication of CN113233976B publication Critical patent/CN113233976B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/342Alcohols having more than seven atoms in an unbroken chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/345Alcohols containing more than one hydroxy group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • A61K8/604Alkylpolyglycosides; Derivatives thereof, e.g. esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/731Cellulose; Quaternized cellulose derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8147Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86Polyethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/48Thickener, Thickening system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers
    • A61K2800/524Preservatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures
    • A61K2800/592Mixtures of compounds complementing their respective functions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

The invention discloses a gallic acid-aminoacetic acid eutectic crystal and a whitening cream containing the eutectic crystal.

Description

Gallic acid and aminoacetic acid eutectic and whitening cream containing eutectic
Technical Field
The invention relates to the field of cosmetics, in particular to a gallic acid and aminoacetic acid eutectic crystal, a whitening cream containing the eutectic crystal and a preparation method of the whitening cream.
Background
Gallic acid is also called gallic acid or gallic acid, chemical name is 3, 4, 5 trihydroxy benzoic acid, chemical formula C6H2(OH)3COOH, needle-like crystals, melting point 235-. The result of the research on the in-vitro antioxidant capacity of the gallic acid by the Xianyan and the like also shows that compared with the accepted antioxidant vitamin C, the gallic acid has a certain concentration dependence relationship in the concentration range of 5-50mg/L to eliminate the 2, 2-biphenyl-1-pichydrazide radical, and the clearance rate of the gallic acid to the vitamin C is far greater; the removal effect of gallic acid on hydroxyl free radicals is obviously higher than that of vitamin C within the range of 50-400 mg/L, and gallic acid with different concentrations has the inhibition effect on lipid peroxidation, and the inhibition rate is higher than that of vitamin C.
Cocrystals are crystals formed by the combination of a pharmaceutically active ingredient (API) and a cocrystal former (CCF, or another API) via hydrogen bonding or other non-covalent bonds, wherein the pure states of API and CCF are both solid at room temperature and have a fixed stoichiometric ratio between the components. By forming a co-crystal, properties of the API, such as increased solubility, dissolution and transdermal absorption, improved release characteristics, etc., can be greatly improved. Common methods for preparing the co-crystals include: solvent evaporation, solvothermal, cooling crystallization, sublimation, melting, suspension crystallization, milling, ultrasound, and the like. The eutectic can improve the dissolution rate and the transdermal absorption rate of insoluble substances, and is a new technical development trend of cosmetic combination. Gallic acid and aminoacetic acid eutectic have been reported in the literature, but no research on the application of gallic acid and aminoacetic acid eutectic in cosmetics has been found so far.
Disclosure of Invention
The invention aims to provide a compound cosmetic containing gallic acid-aminoacetic acid eutectic and a preparation method thereof.
The gallic acid-aminoacetic acid eutectic exists in a stable eutectic form, the molar ratio of the gallic acid to the aminoacetic acid is 1:1, and the gallic acid-aminoacetic acid eutectic is prepared by adopting an absolute ethyl alcohol solvent assisted wet grinding method. Gallic acid was purchased from beijing carbofuran technologies ltd, content: 99.0 percent; aminoacetic acid was purchased from bailcarb technologies ltd, beijing.
Further, the preparation method of the gallic acid-glycine eutectic is an absolute ethyl alcohol solvent assisted wet grinding method, the gallic acid and the glycine are respectively mixed according to a molar ratio of 1:1, the mixture is placed in a mortar, 1mL of absolute ethyl alcohol is added for grinding, 1mL of absolute ethyl alcohol is dropwise added every 2 minutes for grinding, so that a sample is always kept in a slurry state in the whole grinding process, the grinding time is 30min, and the sample is dried in a vacuum drier for later use. The grinding method mixes different drug molecules uniformly by mechanical force, and the two drug molecules generate acting forces with different strengths such as hydrogen bond, dipole moment, van der waals force and the like according to the structural characteristics of the two drug molecules, so that a eutectic can be formed. Characterization of gallic acid-glycine co-crystal:
(1) x-ray powder diffraction (PXRD) analysis is used for evaluating the state of substances in the gallic acid-aminoacetic acid drug composition, and about 50mg of a sample to be tested is taken to perform X-ray powder diffraction at room temperature. Adopting a Cu-Kalpha target, filtering by a graphite crystal monochromator, and obtaining the following working voltage: 20kV, receiving slit: 0.3mm, 2 θ angle: 5-40 DEG, step length: 0.05 °, diffraction patterns and data were recorded directly by the computer. A new peak different from the peak of gallic acid-glycine crystals appeared at 26.3 ° 2 θ, indicating the formation of a eutectic of gallic acid and glycine. 3 portions of gallic acid,4. Containing O-H in both the 5-positions and being able to form C ═ O with C ═ O in glycineO-H hydrogen bonds, thereby forming a new gallic acid-aminoacetic acid eutectic. Please refer to fig. 1.
(2) And evaluating the substance state of the gallic acid-aminoacetic acid drug combination by differential scanning calorimetry. Thermal analysis is carried out on gallic acid monomer, aminoacetic acid monomer and gallic acid-aminoacetic acid eutectic (1: 1) by adopting differential scanning calorimetry. The experimental method comprises the following steps: precisely weighing 3-5 mg of a sample to be measured, placing the sample in an aluminum sample crucible, taking a reference object as an empty aluminum crucible, heating the sample from room temperature to 450 ℃ at the heating rate of 10 ℃/min, and taking nitrogen as the atmosphere. In the DSC curve, please refer to fig. 2, a new peak appears at 163 ℃ in the gallic acid-aminoacetic acid eutectic, indicating the formation of gallic acid-aminoacetic acid eutectic. Melting point peaks of gallic acid and aminoacetic acid are respectively at 272 ℃ and 268 ℃, when gallic acid-aminoacetic acid eutectic is 1:1, two peaks at 272 ℃ and 268 ℃ disappear, and simultaneously, a melting point peak of the eutectic appears at 163 ℃.
(3) Evaluation of dissolution test
The dissolution test is carried out by referring to the fourth general rule dissolution and release determination method II (paddle method) of the Chinese pharmacopoeia 2015 edition. Taking 50mg of gallic acid standard substance, wherein gallic acid and aminoacetic acid 1:1 eutectic are equivalent to 50mg of gallic acid, taking 900mL of 0.1mol/L hydrochloric acid solution as a dissolution medium, stirring at a constant speed of 50r/min, measuring in a circulating water bath at 37 +/-0.5 ℃, sampling at 1,3, 5, 7, 9, 11, 13, 15 and 20min respectively, sampling 5mL of the dissolution medium each time, filtering through a 0.45 mu m polytetrafluoroethylene membrane, collecting subsequent filtrate, placing the subsequent filtrate in a test tube, supplementing 5mL of dissolution medium preheated to 37 ℃ into a dissolution cup, measuring the absorbance of the sample in each test tube at 259nm, calculating the amount of free gallic acid according to a standard curve, calculating the dissolution rate of the gallic acid at each time point, and drawing an in-vitro dissolution curve of the gallic acid. Referring to fig. 3, the dissolution rate of gallic acid after the gallic acid-aminoacetic acid eutectic is prepared is significantly improved compared with the gallic acid-aminoacetic acid physical mixture. It can be found that the cumulative dissolution amount of gallic acid-aminoacetic acid in 3min is more than 85%.
(4) Transdermal absorption test
The culture conditions of Caco-2 cells are as follows: DMEM high-sugar medium containing 10% fetal calf serum, 1% double antibody and 1% nonessential amino acids is used for culture in a biological incubator at 37 ℃ and under the conditions of 95% relative humidity and 5% CO 2. Caco-2 simulated small intestine epithelial cell transfer experiment adopts Caco-2 cell strain growing and differentiating to 30 generations, after cell differentiation and fusion reach 80%, using pancreatin to digest, using complete culture medium to regulate cell suspension concentration to be 1.5X 105cells/mL were inoculated into a 12-well Transwell cuvette, and 0.5mL of the cell fluid was added to the upper layer (AP side) of the Transwell, while 1.5mL of the medium was added to the lower layer (BL side) of the Transwell. The medium was changed every other day, cell morphology was observed, and after continuous culture for 21 days, permeation experiments were started. Appropriate amounts of gallic acid and gallic acid-glycine (molar ratio 1:1) were dispersed in pH7.4 (containing HBSS and 25mM HEPES buffer) to prepare a suspension solution of 20. mu.g/mL in terms of gallic acid, which was used as the group 2 administration groups. pH7.4 (containing HBSS, 25mM HEPES and 4% BSA) was used as a receiving solution. 0.4mL of a 20. mu.g/ML gallic acid-administered solution was added to the AP side as a test solution, and 1.2mL of a culture solution having a pH of 7.4 was added to the BP side. Each group of 4 duplicate wells. The 12-well plate was incubated on a 37 ℃ temperature-controlled shaker at 100rpm to begin the transport experiment. Sampling every 20min, acting for 2h, pretreating the sample, and analyzing the content of gallic acid by HPLC liquid phase. The chromatographic conditions are as follows: with Diamonsil C18A (250X 4.6mm, 5 μm) chromatographic column as a stationary phase, an acetonitrile-0.03% phosphoric acid solution (10:90) as a mobile phase, a detection wavelength of 259nm, a column temperature of 30 ℃, a flow rate: 0.6mL/min, injection volume: 25 μ l. The apparent permeability coefficient Papp is calculated. The calculation result of the apparent permeability coefficient Papp is shown in figure 4, which shows that the gallic acid-aminoacetic acid permeability is obviously improved.
The gallic acid-aminoacetic acid eutectic whitening cream is characterized in that the weight percentage of the gallic acid-aminoacetic acid eutectic is 0.2% -5%, when the content of the gallic acid-aminoacetic acid eutectic is lower than 0.2%, the whitening effect is not obvious, when the addition amount of the gallic acid-aminoacetic acid eutectic is higher than 5%, the formula cost is overhigh, and the skin discomfort caused by the heat sensation is caused. For example, the gallic acid-glycine co-crystal can be added in an amount of 0.2%, 0.3%, 0.5%, 1.0%, 2.0%, 3.5%, 5%, etc.
In some embodiments, the whitening cream further comprises one or more of an emulsifier, a thickener, a humectant, and a preservative;
preferably, the weight percentage of the emulsifier is 2% -15%, preferably 2% -10%;
preferably, the weight percentage of the thickening agent is 2% -10%, preferably 2% -8%;
preferably, the weight percentage of the humectant is 12-20%, preferably 12-17%;
preferably, the weight percentage of the preservative is 0.1-1%, preferably 0.1-0.5%.
In some embodiments, the emulsifier is formulated from behenyl alcohol, and arachidyl glucoside (Montanov202) and glyceryl stearate PEG-100 stearate (SIMULSOL 165). The selection of the emulsifier has an influence on the appearance, absorption effect, spreadability, size and uniformity of the dispersed particle size of the cream sample, especially stability. Therefore, the whitening cream is required to have the quality of modern cosmetics and to be stable and effective. The research finds that when the whitening cream uses a compound emulsifier of the docosanol, the eicosyl glucoside (Montanov202) and the glyceryl stearate PEG-100 stearate (SIMULSOL 165), the cream has excellent appearance, spreadability, absorption effect, viscosity, emulsified particle size and other indexes.
In some embodiments, the thickener is formulated from hydroxyethylcellulose and polyacrylic acid 13/polyisobutylene/polysorbate 20(Sepiplus 400). The effect of different thickening systems on the final sample, which is not only manifested in the stability and appearance of the sample, but also in the feel of use and the efficacy properties of the sample, will vary as well, being one of the important components of a thickening system in a cosmetic formulation. The experimental cream needs to be added with plant extracts with higher ion content, when a thickening system of a formula is designed, an ion-resistant thickening agent is selected, and the ion-resistant hydroxyethyl cellulose and SEPIPLUS400 are selected to be compounded with each other, so that the requirement of formula design is met.
In some embodiments, the humectant is selected from one or more of 1, 3-propanediol, propylene glycol, pentanediol, hexanediol, sorbitol, glycerol, dipropylene glycol, 1, 3-butanediol, trehalose, xylitol, erythritol, glyceryl polyether-26, β -glucan, methyl glucitol polyether-20, methyl glucitol polyether-10, erythrulose, biogan-1, betaine, rhamnose, oat β -glucan, acetyl chitosamine, polyethylene glycols, water-soluble fats and oils, water-soluble silicone oils, and sodium hyaluronate.
In some embodiments, the preservative is a combination of ZANTHOXYLUM BUNGEANUM (ZANTHOXYLUM BUNGEANUM) fruit extract, PULSATILLA CHINENSIS (PULSATILLA CHINENSIS) extract, and spanish moss (TILLANDSIA USNEOIDES) extract.
In some embodiments, the whitening cream comprises the following components in percentage by weight as shown in the table:
Figure BDA0003055665620000071
also provided in some embodiments is a method of preparing the whitening cream, the method comprising the steps of:
(1) adding deionized water into a water phase pot, adding docosyl alcohol, eicosyl glucoside, glyceryl stearate PEG-100 stearate, glycerol, 1, 3-propylene glycol and betaine under stirring, stirring uniformly, and heating to 85 deg.C for dissolving.
(2) Adding hydroxyethyl cellulose into an oil phase pot, heating to 80 ℃, and dissolving for later use.
(3) Preheating an emulsifying pot to 85 ℃, adding the phase (1), then adding the phase (2) and polyacrylic acid 13/polyisobutylene/polysorbate 20(Sepiplus400), homogenizing and emulsifying (3200R/min) for 5min, stirring (25R/min), vacuumizing to 0.4 atmospheric pressure, and slowly cooling with cooling water to 45 ℃ for later use.
(4) Adding gallic acid-aminoacetic acid eutectic and fructus Zanthoxyli (Zanthoxylum BUNGEANUM) fruit extract, radix Pulsatillae (Pulsatilla CHINENSIS) extract, and Spanish moss (TILLANDSIA USNEOIDES) extract into (3), stirring (15R/min) for 15 min, discharging at 38 deg.C, and storing and standing.
Compared with the prior art, the gallic acid-aminoacetic acid in the cosmetic exists in a cocrystallization state, the synergistic effect of the gallic acid and the aminoacetic acid is exerted, the dissolution rate of the gallic acid is improved, the transdermal absorption capacity of the gallic acid is increased, and the curative effect of the cosmetic is improved.
Drawings
FIG. 1 is an X-ray powder diffraction PXRD pattern.
Figure 2 is a differential scanning calorimetry, DSC, graph.
FIG. 3 is a graph showing the results of dissolution test.
FIG. 4 is a graph showing the results of apparent permeability coefficients of Caco-2 cell permeation experiments.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Examples 1 to 5: effect of emulsifiers on the sensory Effect of whitening creams
According to international standard ISO8589-2007 general guideline for design sensory analysis laboratory and national standard GB/T13868-2009 general knowledge principle for sensory analysis-establishment sensory analysis laboratory, etc., volunteers require: the number of 20 healthy people aged 20-30 years, the volunteers with unlimited characters fill in corresponding feeling evaluation tables according to the feelings during and after use, all the feelings are represented by numbers, the trial process adopts a double-blind method, namely, each volunteer does not know the real information of a sample and the feelings of other volunteers, and the research process is carried out independently. All data are summarized and subjected to statistical analysis to obtain the final evaluation of the tested sample. Preferably 9 to 10 minutes; preferably 7 to 8 minutes; generally 5 to 6 points; worse 3-4 points; very poor 1-2 points.
The effect of each emulsifier was examined with the basic formulation in table 1:
Figure BDA0003055665620000091
Figure BDA0003055665620000101
table 2 shows the results of the evaluation of the effect of the various emulsifiers when the basic formulation in Table 1 is unchanged: wherein the emulsifier is: example 1: isostearyl glucoside
Example 2: ceteareth-25
Example 3: tween-60 and span 60
Example 4: brij 72 and Briji 721 both: polyoxyethylene (2) stearyl alcohol ether and polyoxyethylene (21) stearyl alcohol ether
Example 5: montanov202 and SIMULSOL 165 both: behenyl alcohol and arachidyl glucoside and glyceryl stearate PEG-100 stearate
Figure BDA0003055665620000102
Figure BDA0003055665620000111
It can be seen from examples 1-5 that the moisturizing effect and the refreshing degree of the cream are not greatly affected by the emulsifier, mainly the moisturizing effect and the refreshing degree are more affected by the humectant and the grease, and the combination of different emulsifiers has little effect on the moisturizing effect and the refreshing degree under the condition that the basic formula is not changed. The cream appearance, spreading emulsifier example 3, 4, 5, worked better than the other example 1, 2. The five groups of emulsifiers have the greatest influence on the absorption effect and viscosity of the cream, wherein the groups of examples 3 and 5 are better than the groups of other examples 1, 2 and 4. Wherein the particle size, particle size uniformity (distribution), and particle size regularity of the examples 4 and 5 were observed by microscope, which is better than those of the other examples 1, 2, and 3. In summary of the results, the Montanov202 and SIMULSOL 165 of example 5, i.e., behenyl alcohol and arachidyl glucoside, and glyceryl stearate PEG-100 stearate emulsifiers, are better.
Examples 6 to 12: whitening effect test of whitening cream product
TABLE 3 whitening cream formulations of examples 6-12
Figure BDA0003055665620000112
Figure BDA0003055665620000121
Comparative examples 1 to 5 preparation
Comparative examples 1-5, the same weight percentages of emulsifier, humectant, thickener, preservative and deionized water as in example 6, except that comparative example 1 is a blank, comparative example 2 adds 5% gallic acid monomer, comparative example 3 adds 5% glycine monomer, comparative example 4 adds a gallic acid-glycine physical mixture, where the gallic acid content is equivalent to 5%, and comparative example 5 is 5% commercially available vitamin C.
Determination of melanin: the skin melanin tester MDD4-Mexameter MX18 is used for detection, during testing, the probe is vertically pressed on the skin surface of a testee, a spring for ensuring constant pressure during each test is arranged in the probe, and after each test, the skin melanin value is displayed on a display screen. The instrument is based on the principle of spectral absorption, and the content of melanin and heme in skin is determined by measuring the reflection quantity of light with specific wavelength irradiated on the skin of a human body. A smaller melanin number indicates a whiter skin, whereas a darker skin is indicated. The subject's requirements: selecting healthy people of 20-25 years old without skin disease history and cosmetic allergy history. The results are shown in Table 4.
Figure BDA0003055665620000131
Figure BDA0003055665620000141
As can be seen from table 4, the content of melanin of comparative example 1 has no significant difference (P >0.05) compared to the content of melanin before application on days 7, 14 and 28, respectively, indicating that the basic formula without gallic acid-glycine has no whitening effect. In example 6 (the added amount of gallic acid-glycine was 0.2%), the melanin content was reduced on the 7 th, 14 th and 28 th days after application, but the reduction was not significant, and was substantially equivalent to the effect of the 5% gallic acid monomer in comparative example 2. The whitening effect of the cream containing gallic acid-aminoacetic acid eutectic 0.2% is weaker. In example 7, the melanin content has no significant difference (P >0.05) between the melanin content before application on the 7 th day and the melanin content before use on the 14 th day, and the melanin content has a significant difference (P <0.05) between the melanin content before application on the 28 th day and the melanin content before use, so that the cream containing gallic acid-glycine eutectic 0.3% starts to have certain whitening effect on the 28 th day of application; in example 8, the melanin content was not significantly different (P >0.05) on the 7 th day of application compared to the melanin content before use, while the melanin content was not significantly different (P <0.05) on the 14 th and 28 th days compared to the melanin content before use, respectively, and the melanin content was not significantly different (P >0.05) on the 14 th and 28 th days, which indicates that 0.5% gallic acid-glycine co-crystal had the whitening effect on the 14 th day, and the whitening effect was gradually stabilized from the 14 th to 28 th days. In example 9, the melanin contents were significantly different (P <0.05) on the 7 th, 14 th and 28 th days of application and the melanin contents were significantly different (P <0.05) on the 7 th and 14 th days and were not significantly different (P >0.05) on the 14 th and 28 th days, indicating that 1.0% gallic acid-glycine co-crystal had a whitening effect on the 7 th day, and the whitening effect was still enhanced from the 7 th to 14 th days, and the whitening effect was gradually stabilized until the 14 th day. In examples 10 and 11, the melanin contents were significantly different (P <0.05) on the 7 th, 14 th and 28 th days of application and the melanin contents were significantly different (P <0.05) on the 7 th and 14 th days and the melanin contents were significantly different (P <0.05) on the 14 th day and the 28 th day, respectively, indicating that the skin whitening effect was exhibited from the 7 th day to the 14 th day when the gallic acid-glycine co-crystal was 2.0% and 3.5%, and the skin whitening effect was still enhanced from the 7 th to the 14 th days. In example 12, the melanin contents were significantly different (P <0.05) on the 7 th, 14 th and 28 th days of application and the melanin contents were significantly different (P <0.05) on the 7 th and 14 th days of application, and the melanin and heme contents were not significantly different (P >0.05) on the 14 th and 28 th days of application, which indicates that gallic acid-glycine eutectic 5.0% had the whitening effect on the 7 th day, and the whitening effect was still enhanced from the 7 th to 14 th days, and the whitening effect was gradually stabilized after the 14 th day. From examples 6-12, it can be seen that the whitening effect of the picric acid-glycine co-crystal is gradually increased with the increase of the content, but the increase to 5% tends to be smooth.
Example 13: preparation of whitening creams of examples 6 to 12
(1) Adding deionized water into a water phase pot, adding docosyl alcohol, eicosyl glucoside, glyceryl stearate PEG-100 stearate, glycerol, 1, 3-propylene glycol and betaine under stirring, stirring uniformly, and heating to 85 deg.C for dissolving.
(2) Adding hydroxyethyl cellulose into an oil phase pot, heating to 80 ℃, and dissolving for later use.
(3) Preheating an emulsifying pot to 85 ℃, adding the phase (1), then adding the phase (2) and polyacrylic acid 13/polyisobutylene/polysorbate 20(Sepiplus400), homogenizing and emulsifying (3200R/min) for 5min, stirring (25R/min), vacuumizing to 0.4 atmospheric pressure, and slowly cooling with cooling water to 45 ℃ for later use.
(4) Adding gallic acid-aminoacetic acid eutectic and fructus Zanthoxyli (Zanthoxylum BUNGEANUM) fruit extract, radix Pulsatillae (Pulsatilla CHINENSIS) extract, and Spanish moss (TILLANDSIA USNEOIDES) extract into (3), stirring (15R/min) for 15 min, discharging at 38 deg.C, and storing and standing.
While the foregoing is directed to the preferred embodiment of the present invention, it will be understood by those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention.

Claims (10)

1. The gallic acid and aminoacetic acid eutectic crystal is characterized in that the gallic acid and the aminoacetic acid exist in a stable eutectic crystal form, the molar ratio of the gallic acid to the aminoacetic acid is 1:1, and the gallic acid and the aminoacetic acid eutectic crystal is prepared by adopting an absolute ethyl alcohol solvent assisted wet grinding method.
2. The gallic acid and aminoacetic acid eutectic crystal of claim 1, wherein the anhydrous ethanol solvent assisted wet grinding method comprises mixing gallic acid and aminoacetic acid at a molar ratio of 1:1, placing in a mortar, adding anhydrous ethanol for grinding, adding anhydrous ethanol along the edge to maintain the sample in a slurry state all the time during the whole grinding process, and drying in a vacuum drier for later use.
3. The gallic acid and aminoacetic acid eutectic of claim 2, wherein the amount of added absolute ethanol is 1mL, and 1mL of absolute ethanol is added dropwise every 2min for grinding for 30 min.
4. The gallic acid and aminoacetic acid cocrystal according to claim 3, wherein the gallic acid and aminoacetic acid cocrystal shows a new peak at 26.3 ° 2 θ in X-ray powder diffraction spectrum expressed in degree 2 θ using Cu-K α radiation, and a new peak at 163 ℃ in DSC curve.
5. A whitening cream characterized by comprising the gallic acid and aminoacetic acid eutectic crystal as claimed in any one of claims 1 to 4, wherein the weight percentage of the gallic acid and the aminoacetic acid eutectic crystal is 0.2 to 5 percent.
6. The whitening cream of claim 5, further comprising one or more of an emulsifier, a thickener, a humectant, and a preservative;
preferably, the weight percentage of the emulsifier is 2% -15%, preferably 2% -10%;
preferably, the weight percentage of the thickening agent is 2% -10%, preferably 2% -8%;
preferably, the weight percentage of the humectant is 12-20%, preferably 12-17%;
preferably, the weight percentage of the preservative is 0.1-1%, preferably 0.1-0.5%.
7. The whitening cream according to claim 6, wherein the emulsifier is compounded from Montanov202 and SIMULSOL 165.
8. The whitening cream according to claim 6, wherein the thickener is formulated from hydroxyethyl cellulose and Sepiplus 400.
9. The whitening cream according to claim 6, wherein the humectant is selected from one or more of 1, 3-propylene glycol, pentylene glycol, hexylene glycol, sorbitol, glycerin, dipropylene glycol, 1, 3-butylene glycol, trehalose, xylitol, erythritol, glyceryl polyether-26, β -glucan, methyl glucitol polyether-20, methyl glucitol polyether-10, erythrulose, biogum-1, betaine, rhamnose, oat β -glucan, acetyl chitosamine, polyethylene glycols, water-soluble oils, water-soluble silicone oils, and sodium hyaluronate.
The preservative is a compound of a zanthoxylum bungeanum maxim extract, a Chinese pulsatilla root extract and a Spanish moss extract.
10. The whitening cream according to any one of claims 6 to 9, comprising the following components in percentage by weight:
Figure FDA0003055665610000021
Figure FDA0003055665610000031
CN202110499029.9A 2021-05-08 2021-05-08 Gallic acid and aminoacetic acid eutectic and whitening cream containing eutectic Active CN113233976B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110499029.9A CN113233976B (en) 2021-05-08 2021-05-08 Gallic acid and aminoacetic acid eutectic and whitening cream containing eutectic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110499029.9A CN113233976B (en) 2021-05-08 2021-05-08 Gallic acid and aminoacetic acid eutectic and whitening cream containing eutectic

Publications (2)

Publication Number Publication Date
CN113233976A true CN113233976A (en) 2021-08-10
CN113233976B CN113233976B (en) 2021-11-16

Family

ID=77132476

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110499029.9A Active CN113233976B (en) 2021-05-08 2021-05-08 Gallic acid and aminoacetic acid eutectic and whitening cream containing eutectic

Country Status (1)

Country Link
CN (1) CN113233976B (en)

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62135388A (en) * 1985-12-09 1987-06-18 Ricoh Co Ltd Thermal recording material
WO2012090224A1 (en) * 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug
WO2012150537A2 (en) * 2011-05-04 2012-11-08 Laboratorios Senosiain S.A. De C.V. Novel solid forms of antibiotics
CN102964384A (en) * 2012-11-09 2013-03-13 中山大学 Adefovir dipivoxil gallic acid eutectic, and preparation method and composition thereof
CN105367549A (en) * 2015-11-26 2016-03-02 中山大学 Lenalidomide-gallic acid co-crystal and preparation method therefor
CN106083743A (en) * 2016-06-20 2016-11-09 广州大学 A kind of glycine anhydride eutectic as medicinal premixing auxiliary material and preparation method and application
CN106659693A (en) * 2014-07-02 2017-05-10 布拉德福德大学 Effervescent compositions containing co-crystals of the acid part
CN107468584A (en) * 2017-09-13 2017-12-15 泾县麦蓝网络技术服务有限公司 A kind of crease-resistant shine white composition and preparation method thereof and the application in cosmetics
CN109431908A (en) * 2018-12-26 2019-03-08 广州市科能化妆品科研有限公司 Skin whitening, moisturizing frost and preparation method thereof and skin-lightening cosmetic additive
US20190275056A1 (en) * 2007-06-06 2019-09-12 University Of South Florida Nutraceutical co-crystal compositions
CN110520117A (en) * 2017-02-13 2019-11-29 心悦生医股份有限公司 Substituted eutectic of glycine compound and application thereof
WO2019227202A1 (en) * 2018-05-31 2019-12-05 The Royal Institution For The Advancement Of Learning/Mcgill University PHARMACEUTICAL SALTS/CO-CRYSTALS OF PENTOXIFYLLINE, CLONIDINE AND LINSIDOMINE WITH CAFFEIC, PROTOCATECHUIC OR α-LIPOIC ACID AN USE THEREOF FOR TREATMENT OF PAIN
CN111574359A (en) * 2019-02-19 2020-08-25 愈磐生物科技(苏州)有限公司 Levatinib-gallic acid eutectic crystal form and application thereof
WO2021034150A1 (en) * 2019-08-21 2021-02-25 주식회사 엘지생활건강 Cosmetic composition comprising eutectic mixture

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62135388A (en) * 1985-12-09 1987-06-18 Ricoh Co Ltd Thermal recording material
US20190275056A1 (en) * 2007-06-06 2019-09-12 University Of South Florida Nutraceutical co-crystal compositions
WO2012090224A1 (en) * 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug
WO2012150537A2 (en) * 2011-05-04 2012-11-08 Laboratorios Senosiain S.A. De C.V. Novel solid forms of antibiotics
CN102964384A (en) * 2012-11-09 2013-03-13 中山大学 Adefovir dipivoxil gallic acid eutectic, and preparation method and composition thereof
CN106659693A (en) * 2014-07-02 2017-05-10 布拉德福德大学 Effervescent compositions containing co-crystals of the acid part
CN105367549A (en) * 2015-11-26 2016-03-02 中山大学 Lenalidomide-gallic acid co-crystal and preparation method therefor
CN106083743A (en) * 2016-06-20 2016-11-09 广州大学 A kind of glycine anhydride eutectic as medicinal premixing auxiliary material and preparation method and application
CN110520117A (en) * 2017-02-13 2019-11-29 心悦生医股份有限公司 Substituted eutectic of glycine compound and application thereof
CN107468584A (en) * 2017-09-13 2017-12-15 泾县麦蓝网络技术服务有限公司 A kind of crease-resistant shine white composition and preparation method thereof and the application in cosmetics
WO2019227202A1 (en) * 2018-05-31 2019-12-05 The Royal Institution For The Advancement Of Learning/Mcgill University PHARMACEUTICAL SALTS/CO-CRYSTALS OF PENTOXIFYLLINE, CLONIDINE AND LINSIDOMINE WITH CAFFEIC, PROTOCATECHUIC OR α-LIPOIC ACID AN USE THEREOF FOR TREATMENT OF PAIN
CN109431908A (en) * 2018-12-26 2019-03-08 广州市科能化妆品科研有限公司 Skin whitening, moisturizing frost and preparation method thereof and skin-lightening cosmetic additive
CN111574359A (en) * 2019-02-19 2020-08-25 愈磐生物科技(苏州)有限公司 Levatinib-gallic acid eutectic crystal form and application thereof
WO2021034150A1 (en) * 2019-08-21 2021-02-25 주식회사 엘지생활건강 Cosmetic composition comprising eutectic mixture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ACHILLIA LAKKA ET AL.: ""Saffron Processing Wastes as a Bioresource of High-Value Added Compounds: Development of a Green Extraction Process for Polyphenol Recovery Using a Natural Deep Eutectic Solvent"", 《ANTIOXIDANTS》 *

Also Published As

Publication number Publication date
CN113233976B (en) 2021-11-16

Similar Documents

Publication Publication Date Title
US20190240134A1 (en) A skincare cosmetic composition
JPS63192703A (en) External agent for skin
CN108434064A (en) Have both the skin care item of skin anti-inflammatory Eradicates acnes and repair function
JP2010503643A (en) Composition based on xanthoxylin and its use in cosmetics
WO2022105225A1 (en) Azelaic acid gel, preparation method therefor and application thereof
CN109620787A (en) A kind of moisturizing golden hairpin dendrobium extract and the preparation method and application thereof
JP4464533B2 (en) Cosmetics
JPH03258711A (en) Skin-whitening agent for external use
JP5105962B2 (en) Cornified envelope formation / maturation promoter
CN113233976B (en) Gallic acid and aminoacetic acid eutectic and whitening cream containing eutectic
JP2006169188A (en) Skin care preparation for whitening, whitening agent, whitening method and method for producing skin care preparation for whitening
JP3340935B2 (en) Melanin production inhibitor and whitening cosmetic
JPH0812560A (en) Skin external preparation
JP2004115381A (en) External preparation for skin
JPS6026086B2 (en) cosmetics
JP2008303185A (en) Agent for promoting formation and maturation of cornified envelope
JPH0977655A (en) Skin preparation for external use
JP6751829B2 (en) Liquid external preparation
JP3057207B2 (en) External preparation for skin
KR101002432B1 (en) Resveratrol derivative, its preparation method, and cosmetic composition comprising the same
JP5450918B2 (en) Topical skin preparation
JP4223574B2 (en) Cosmetic composition for whitening
JPH02204498A (en) Anthralin.sterol complex, its manufacture, and its medical and cosmetic application
JPH01213213A (en) External preparation composition
JPS62234006A (en) External drug for skin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant